{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:55:00Z","timestamp":1793346900715,"version":"4.5.0"},"reference-count":48,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,2,21]]},"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The phase I first-in-human study ENGAGE-1 evaluated the humanized IgG1 OX40 agonistic monoclonal antibody GSK3174998 alone (Part 1 (P1)) or in combination with pembrolizumab (Part 2 (P2)) in patients with advanced solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>GSK3174998 (0.003\u201310\u2009mg\/kg) \u00b1 pembrolizumab (200\u2009mg) was administered intravenously every 3 weeks using a continuous reassessment method for dose escalation. Primary objectives were safety and tolerability; secondary objectives included pharmacokinetics, immunogenicity, pharmacodynamics, and clinical activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>138 patients were enrolled (45 (P1) and 96 (P2, including 3 crossovers)). Treatment-related adverse events occurred in 51% (P1) and 64% (P2) of patients, fatigue being the most common (11% and 24%, respectively). No dose-toxicity relationship was observed, and maximum-tolerated dose was not reached. Dose-limiting toxicities (P2) included Grade 3 (G3) pleural effusion and G1 myocarditis with G3 increased troponin. GSK3174998 \u22650.3\u2009mg\/kg demonstrated pharmacokinetic linearity and &gt;80% receptor occupancy on circulating T cells; 0.3\u2009mg\/kg was selected for further evaluation. Limited clinical activity was observed for GSK3174998 (P1: disease control rate (DCR) \u226524 weeks 9%) and was not greater than that expected for pembrolizumab alone (P2: overall response rate 8%, DCR \u226524 weeks 28%). Multiplexed immunofluorescence data from paired biopsies suggested that increased infiltration of natural killer (NK)\/natural killer T (NKT) cells and decreased regulatory T cells (Tregs) in the tumor microenvironment may contribute to clinical responses: CD16+CD56\u2013CD134+ NK \/NKT cells and CD3+CD4+FOXP3+CD134+ Tregs exhibited the largest magnitude of change on treatment, whereas CD3+CD8+granzyme B+PD-1+CD134+ cytotoxic\u2009T cells were the least variable. Tumor gene expression profiling revealed an upregulation of inflammatory responses, T-cell proliferation, and NK cell function on treatment with some inflammatory cytokines upregulated in peripheral blood. However, target engagement, evidenced by pharmacologic activity in peripheral blood and tumor tissue, did not correlate with clinical efficacy. The low number of responses precluded identifying a robust biomarker signature predictive of response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GSK3174998\u00b1pembrolizumab was well tolerated over the dose range tested and demonstrated target engagement. Limited clinical activity does not support further development of GSK3174998\u00b1pembrolizumab in advanced cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02528357\">NCT02528357<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2022-005301","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T22:00:20Z","timestamp":1679004020000},"page":"e005301","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":58,"title":["First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct02528357","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02528357","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02410512","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5562-1857","authenticated-orcid":false,"given":"Sophie","family":"Postel-Vinay","sequence":"first","affiliation":[{"name":"D\u00e9partement d\u2019Innovation Th\u00e9rapeutique et d\u2019Essais Pr\u00e9coces (DITEP), Gustave Roussy, Universit\u00e9 Paris Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent K","family":"Lam","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willeke","family":"Ros","sequence":"additional","affiliation":[{"name":"Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M","family":"Bauer","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron R","family":"Hansen","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C","family":"Cho","sequence":"additional","affiliation":[{"name":"New York Medical College, Valhalla, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Stephen Hodi","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H M","family":"Schellens","sequence":"additional","affiliation":[{"name":"Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K","family":"Litton","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Aspeslagh","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019Innovation Th\u00e9rapeutique et d\u2019Essais Pr\u00e9coces (DITEP), Gustave Roussy, Universit\u00e9 Paris Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0720-0390","authenticated-orcid":false,"given":"Karen A","family":"Autio","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans L","family":"Opdam","sequence":"additional","affiliation":[{"name":"Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"McKean","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeta","family":"Somaiah","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Champiat","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019Innovation Th\u00e9rapeutique et d\u2019Essais Pr\u00e9coces (DITEP), Gustave Roussy, Universit\u00e9 Paris Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9229-156X","authenticated-orcid":false,"given":"Mehmet","family":"Altan","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3034-3042","authenticated-orcid":false,"given":"Anna","family":"Spreafico","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Rahma","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine M","family":"Paul","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph M","family":"Ahlers","sequence":"additional","affiliation":[{"name":"Replimune Group Inc, Woburn, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Zhou","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Struemper","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelby A","family":"Gorman","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Watmuff","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin M","family":"Yablonski","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niranjan","family":"Yanamandra","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Chisamore","sequence":"additional","affiliation":[{"name":"Merck & Co Inc, Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmett V","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Merck & Co Inc, Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Hoos","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5816-3019","authenticated-orcid":false,"given":"Aurelien","family":"Marabelle","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019Innovation Th\u00e9rapeutique et d\u2019Essais Pr\u00e9coces (DITEP), Gustave Roussy, Universit\u00e9 Paris Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4962-2957","authenticated-orcid":false,"given":"Jeffrey S","family":"Weber","sequence":"additional","affiliation":[{"name":"Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John V","family":"Heymach","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"key":"2025100315273701000_11.3.e005301.1","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"2025100315273701000_11.3.e005301.2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83871"},{"key":"2025100315273701000_11.3.e005301.3","unstructured":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc . Keytruda (pembrolizumab) [package insert]. Rahway, NJ, USA, 2021."},{"key":"2025100315273701000_11.3.e005301.4","unstructured":"Bristol Myers Squibb Company . Yervoy (ipilimumab) [package insert]. Princeton, NJ, 2021."},{"key":"2025100315273701000_11.3.e005301.5","unstructured":"Bristol Myers Squibb Company . Opdivo (nivolumab) [package insert]. Princeton, NJ, 2021."},{"key":"2025100315273701000_11.3.e005301.6","unstructured":"Genentech, Inc . Tecentriq (atezolizumab) [package insert]. South San Francisco, CA, 2021."},{"key":"2025100315273701000_11.3.e005301.7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025100315273701000_11.3.e005301.8","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-Related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025100315273701000_11.3.e005301.9","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2019.12.010","article-title":"Resistance to checkpoint inhibition in cancer immunotherapy","volume":"13","author":"Barrueto","year":"2020","journal-title":"Transl Oncol"},{"key":"2025100315273701000_11.3.e005301.10","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000573","article-title":"New pathways in immune stimulation: targeting OX40","volume":"5","author":"Alves Costa Silva","year":"2020","journal-title":"ESMO Open"},{"key":"2025100315273701000_11.3.e005301.11","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrd.2018.75","article-title":"The promise and challenges of immune agonist antibody development in cancer","volume":"17","author":"Mayes","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"2025100315273701000_11.3.e005301.12","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-030409-101243"},{"key":"2025100315273701000_11.3.e005301.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2017.01.006"},{"key":"2025100315273701000_11.3.e005301.14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0603107103"},{"key":"2025100315273701000_11.3.e005301.15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202752"},{"key":"2025100315273701000_11.3.e005301.16","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-20656-y","article-title":"Augmentation of CD134 (OX40) -dependent NK anti-tumour activity is dependent on antibody cross-linking","volume":"8","author":"Turaj","year":"2018","journal-title":"Sci Rep"},{"key":"2025100315273701000_11.3.e005301.17","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20071341"},{"key":"2025100315273701000_11.3.e005301.18","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2014.26"},{"key":"2025100315273701000_11.3.e005301.19","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-4174"},{"key":"2025100315273701000_11.3.e005301.20","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.3079","article-title":"First in human (FIH) study of an OX40 agonist monoclonal antibody (mab) PF-04518600 (PF-8600) in adult patients (PTS) with select advanced solid tumors: preliminary safety and pharmacokinetic (pk)\/pharmacodynamic results","volume":"34","author":"Hamid","year":"2016","journal-title":"JCO"},{"key":"2025100315273701000_11.3.e005301.21","doi-asserted-by":"crossref","first-page":"LB","DOI":"10.1158\/1538-7445.AM2018-LB-127","article-title":"Abstract lb-127: from bench to bedside: exploring OX40 receptor modulation in a phase 1\/2a study of the OX40 costimulatory agonist BMS-986178 \u00b1 nivolumab (NIVO) or ipilimumab (IPI) in patients with advanced solid tumors","volume":"78","author":"Wang","year":"2018","journal-title":"Cancer Res"},{"key":"2025100315273701000_11.3.e005301.22","article-title":"OX40 T-cell costimulatory agonist BMS-986178 alone or in combination with nivolumab in patients with advanced solid tumors: initial phase 1 results [oral presentation]","volume":"5","author":"Olszanski","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2025100315273701000_11.3.e005301.23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089350","article-title":"PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer","volume":"9","author":"Guo","year":"2014","journal-title":"PLoS ONE"},{"key":"2025100315273701000_11.3.e005301.24","doi-asserted-by":"crossref","first-page":"viii424","DOI":"10.1093\/annonc\/mdy288.065","article-title":"Evaluation of OX40 receptor density, influence of igg isotype and dosing paradigm in anti-OX40-mediated efficacy and biomarker responses with PD-1 blockade","volume":"29","author":"Jackson","year":"2018","journal-title":"Annals of Oncology"},{"key":"2025100315273701000_11.3.e005301.25","doi-asserted-by":"publisher","DOI":"10.1177\/1740774508089279"},{"key":"2025100315273701000_11.3.e005301.26","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3230"},{"key":"2025100315273701000_11.3.e005301.27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-9868.2010.00749.x"},{"key":"2025100315273701000_11.3.e005301.28","unstructured":"R Core Team . R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, Available: https:\/\/www.R-project.org\/"},{"key":"2025100315273701000_11.3.e005301.29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1830"},{"key":"2025100315273701000_11.3.e005301.30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3070"},{"key":"2025100315273701000_11.3.e005301.31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0845"},{"key":"2025100315273701000_11.3.e005301.32","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1158\/1078-0432.CCR-21-4020","article-title":"First-In-Human phase I study of the OX40 agonist MOXR0916 in patients with advanced solid tumors","volume":"28","author":"Kim","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025100315273701000_11.3.e005301.33","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-006-0225-8"},{"key":"2025100315273701000_11.3.e005301.34","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-016-2597-2","article-title":"Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators","volume":"16","author":"Wu","year":"2016","journal-title":"BMC Cancer"},{"key":"2025100315273701000_11.3.e005301.35","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-1106-3"},{"key":"2025100315273701000_11.3.e005301.36","first-page":"3572","article-title":"Adriamycin-Induced modulation of host defenses in tumor-bearing mice","volume":"52","author":"Maccubbin","year":"1992","journal-title":"Cancer Res"},{"key":"2025100315273701000_11.3.e005301.37","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2016-4864","article-title":"Abstract 4864: engaging the immune system with GSK3174998, a potent anti-OX40 agonist antibody","volume":"76","author":"Toniatti","year":"2016","journal-title":"Cancer Res"},{"key":"2025100315273701000_11.3.e005301.38","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.2147\/CMAR.S151023","article-title":"Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data","volume":"11","author":"du Rusquec","year":"2019","journal-title":"Cancer Manag Res"},{"key":"2025100315273701000_11.3.e005301.39","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005471","article-title":"First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors","volume":"10","author":"Hamid","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100315273701000_11.3.e005301.40","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1200\/JCO.2016.34.15_suppl.101","article-title":"A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors","volume":"34","author":"Infante","year":"2016","journal-title":"JCO"},{"key":"2025100315273701000_11.3.e005301.41","unstructured":"Roche . Summary of clinical trial results. A study to look at how safe different doses of MOXR0916 were for patients with cancer - when combined with one or two other medicines. layperson summary. 2020. Available: https:\/\/forpatients.roche.com\/content\/dam\/patient-platform\/lps\/genentech\/nct02410512\/GO29674_final-results-summary_2020July_English.pdf"},{"key":"2025100315273701000_11.3.e005301.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.008"},{"key":"2025100315273701000_11.3.e005301.43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0526"},{"key":"2025100315273701000_11.3.e005301.44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2677"},{"key":"2025100315273701000_11.3.e005301.45","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0292"},{"key":"2025100315273701000_11.3.e005301.46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2009.00766.x"},{"key":"2025100315273701000_11.3.e005301.47","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0454-3","article-title":"Agonist redirected checkpoint, PD1-fc-OX40L, for cancer immunotherapy","volume":"6","author":"Fromm","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2025100315273701000_11.3.e005301.48","article-title":"494 phase 1 dose escalation and dose expansion study of an agonist redirected checkpoint (ARC) fusion protein, SL-279252 (PD1-fc-OX40L), in subjects with advanced solid tumors or lymphomas","volume":"9","author":"Johnson","year":"2021","journal-title":"J Immunother Cancer"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-005301","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T22:27:46Z","timestamp":1759530466000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-005301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,16]]},"published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1136\/jitc-2022-005301"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-005301","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]}}}